Clinical trials recruiting for Colorectal Cancer Metastatic
44
Recruiting trials
5
US states with sites
14
Countries
2%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Bevacizumab | 4 |
| Cetuximab | 3 |
| Irinotecan | 3 |
| Oxaliplatin | 3 |
| Bevacizumab (Avastin) | 2 |
| Capecitabine | 2 |
| Fluorouracil | 2 |
| Sintilimab | 2 |
| ABT-301 | 1 |
| AGEN1423 | 1 |
| Adebrelimab | 1 |
| Anisodamine | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| New York | 4 |
| California | 2 |
| Illinois | 1 |
| Minnesota | 1 |
| North Carolina | 1 |
Top cities
Lake Success, New York 2Chicago, Illinois 1La Jolla, California 1Los Angeles, California 1Morrisville, North Carolina 1New Hyde Park, New York 1New York, New York 1Newport Beach, California 1Rochester, New York 1Saint Louis Park, Minnesota 1
Self-screener
Recruiting trials
- A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer
- A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
- A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
- A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer
- A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer
- BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases
- COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer
- Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
- Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.
- Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
- Colorectal Metastasis to Liver Extraction With Auxiliary Transplant and Delayed Resection
- Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer
- Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
- DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases
- Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
- Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
- Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
- Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
- Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA
- Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods
- FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
- Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
- INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases
- In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung
- Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
- Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
- Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases
- Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases
- Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
- Molecular Characterisation of Colorectal Cancer Peritoneal Metastases
- Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
- PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients with LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)
- Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test
- Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
- Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
- Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)
- Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
- STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
- Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
- TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
- Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)
- Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer
- ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer
- ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
Related conditions
Trials recruiting for Colorectal Cancer Metastatic often also study these conditions. Each links to its own recruiting-trial list.
Colorectal cancer 1359Liver Metastases 30Lung cancer 2180Immunotherapy 40Colorectal Cancer Stage IV 6Colorectal Cancer Recurrent 7Targeted Therapy 8Ras (KRAS or NRAS) Gene Mutation 3Peritoneal Carcinomatosis 10Pancreatic Cancer Non-resectable 10
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Colorectal Cancer Metastatic trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.